Vorasidenib (AG-881): A First-in-Class, Brain-Penetrant Dual Inhibitor of Mutant IDH1 and 2 for Treatment of Glioma

被引：131

作者：

Konteatis, Zenon ^{[1
]}

Artin, Erin ^{[1
,7
]}

Nicolay, Brandon ^{[1
]}

Straley, Kimberly ^{[1
,8
]}

Padyana, Anil K. ^{[1
]}

Jin, Lei ^{[1
]}

Chen, Yue ^{[1
]}

Narayaraswamy, Rohini ^{[1
]}

Tong, Shuilong ^{[2
]}

Wang, Feng ^{[3
]}

Zhou, Ding ^{[4
,9
]}

Cui, Dawei ^{[4
,10
]}

Cai, Zhenwei ^{[4
]}

Luo, Zhiyong ^{[5
]}

Fang, Cheng ^{[5
]}

Tang, Huachun ^{[5
]}

Lv, Xiaobing ^{[5
,14
]}

Nagaraja, Raj ^{[1
]}

Yang, Hua ^{[1
]}

Su, Shin-San M. ^{[1
,12
]}

Sui, Zhihua ^{[1
]}

Dang, Lenny ^{[1
]}

Yen, Katharine ^{[1
,13
]}

Popovici-Muller, Janeta ^{[1
,12
]}

Codega, Paolo ^{[6
,11
]}

Campos, Carl ^{[6
]}

Mellinghoff, Ingo K. ^{[6
]}

Biller, Scott A. ^{[1
]}

机构：

[1] Agios Pharmaceut Inc, Cambridge, MA 02139 USA

[2] Viva Biotech, Shanghai 201203, Peoples R China

[3] Wuxi Biortus Biosci Co Ltd, Jiangyin 214437, Peoples R China

[4] PharmaResources, Shanghai 201201, Peoples R China

[5] ChemPartner, Shanghai 201203, Peoples R China

[6] Mem Sloan Kettering Canc Ctr, New York, NY 10065 USA

[7] KSQ Therapeut, Cambridge, MA 02139 USA

[8] Vertex Pharmaceut, Boston, MA 02210 USA

[9] Zion Pharma, Shanghai 200000, Peoples R China

[10] Suzhou Zelgen Biopharmaceut, Kunshan 215300, Peoples R China

[11] Sundia, Shanghai 201203, Peoples R China

[12] Decibel Therapeut, Cambridge, MA 02215 USA

[13] Auron Therapeut, Wellesley, MA 02481 USA

[14] Italfarmaco SpA, I-20092 Cinisello Balsamo, Italy

来源：

ACS MEDICINAL CHEMISTRY LETTERS | 2020年 / 11卷 / 02期

关键词：

Isocitrate dehydrogenase; mutant IDH1/mIDH2; AG-881; vorasidenib; 2-hydroxyglutarate; GENOMIC ANALYSIS; MUTATIONS;

D O I：

10.1021/acsmedchemlett.9b00509

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Inhibitors of mutant isocitrate dehydrogenase (mIDH) 1 and 2 cancer-associated enzymes prevent the accumulation of the oncometabolite D-2-hydroxyglutarate (2-HG) and are under clinical investigation for the treatment of several cancers harboring an IDH mutation. Herein, we describe the discovery of vorasidenib (AG-881), a potent, oral, brain-penetrant dual inhibitor of both mIDH1 and mIDH2. X-ray cocrystal structures allowed us to characterize the compound binding site, leading to an understanding of the dual mutant inhibition. Furthermore, vorasidenib penetrates the brain of several preclinical species and inhibits 2-HG production in glioma tissue by >97% in an orthotopic glioma mouse model. Vorasidenib represents a novel dual mIDH1/2 inhibitor and is currently in clinical development for the treatment of low-grade mIDH glioma.

引用

页码：101 / 107

页数：13

共 50 条

[31] AG-221, first-in-class IDH2 mutation inhibitor shows promise
Nature Reviews Clinical Oncology, 2014, 11 (6) : 302 - 302
[32] A new era after a long wait: Vorasetinib, an inhibitor of mutant IDH1 and IDH2 enzymes in patients with IDH-mutant glioma
Silvani, Antonio
Franceschi, Enrico
TUMORI JOURNAL, 2024, 110 (03): : 160 - 161
[33] A phase I study of LY3410738, a first-in-class covalent inhibitor of mutant IDH1 in cholangiocarcinoma and other advanced solid tumors.
Pauff, James Michael
Papadopoulos, Kyriakos P.
Janku, Filip
Turk, Anita Ahmed
Goyal, Lipika
Shroff, Rachna T.
Shimizu, Toshio
Ikeda, Masafumi
Azad, Nilofer Saba
Cleary, James M.
Peters, Mary Linton Bounetheau
Borad, Mitesh J.
Jaeckle, Kurt A.
Kizilbash, Sani Haider
Tupper, Rebecca
Furin, Carrie E.
Hanley, Matthew P.
Hill, Elizabeth Goodwin
Xu Xiaojian
Harding, James J.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
[34] IMPACT OF VORASIDENIB TREATMENT ON MUTANT IDH1 OR IDH2 DIFFUSE GLIOMA TUMOR GROWTH RATE: RESULTS FROM THE RANDOMIZED, DOUBLE-BLIND, PHASE 3 INDIGO STUDY
Wen, Patrick
Mellinghoff, Ingo
van den Bent, Martin
Blumenthal, Deborah
Touat, Mehdi
Peters, Katherine
Clarke, Jennifer
Mendez, Joe
Yust-Katz, Shlomit
Mason, Warren
Ducray, Francois
Umemura, Yoshie
Nabors, L. Burt
Holdhoff, Matthias
Hottinger, Andreas
Arakawa, Yoshiki
Sepulveda, Juan
Wick, Wolfgang
Soffietti, Riccardo
Perry, James
Giglio, Pierre
de la Fuente, Macarena
Maher, Elizabeth
Zhao, Dan
Pandya, Shuchi
Steelman, Lori
Hassan, Islam
Cloughesy, Timothy
Ellingson, Benjamin
NEURO-ONCOLOGY, 2023, 25
[35] Discovery of BPI221351, a potent, selective, orally available, and brain penetrating dual inhibitor of mutant IDH1/2
Shen, Hongling
Xu, Xiaofeng
Li, Yabin
Song, Xizhen
Chen, Jie
Bi, Yunting
Guo, Jing
Xu, Tong
Zhang, Huijuan
Liu, Lijia
Zou, Zhengyao
Ren, Jialin
Tong, Jun
Liu, Xiaoyun
Rong, Hongfei
Ma, Teng
Wang, Chao
Liu, Xiangyong
Chen, Hong
Zhao, Jiayu
Ju, Xuepeng
Chen, Haibo
Shen, Haidi
Lan, Hong
Ding, Lieming
Wang, Jiabing
CANCER RESEARCH, 2023, 83 (07)
[36] AG-120, an Oral, Selective, First-in-Class, Potent Inhibitor of Mutant IDH1, Reduces Intracellular 2HG and Induces Cellular Differentiation in TF-1 R132H Cells and Primary Human IDH1 Mutant AML Patient Samples Treated Ex Vivo
Hansen, Erica
Quivoron, Cyril
Straley, Kim
Lemieux, Rene M.
Popovici-Muller, Janeta
Sadrzadeh, Hossein
Fathi, Amir T.
Gliser, Camelia
David, Muriel
Saada, Veronique
Micol, Jean-Baptiste
Bernard, Olivier
Dorsch, Marion
Yang, Hua
Su, Michael
Agresta, Sam
de Botton, Stephane
Penard-Lacronique, Virginie
Yen, Katharine
BLOOD, 2014, 124 (21)
[37] A PHASE 1, MULTICENTER, RANDOMIZED, OPEN-LABEL, PERIOPERATIVE STUDY OF AG-120 (IVOSIDENIB) AND AG-881 IN PATIENTS WITH RECURRENT, NONENHANCING, IDH1-MUTANT, LOW-GRADE GLIOMA
Mellinghoff, Ingo
Maher, Elizabeth
Wen, Patrick
Cloughesy, Timothy
Peters, Katherine
Choi, Changho
Ellingson, Benjamin
Lin, Alexander
Li, Yan
Soher, Brian
Young, Robert
Steelman, Lori
Le, Kha
Yin, Feng
Wu, Bin
Lu, Min
Zhang, Yanwei
Nicolay, Brandon
Schoenfeld, Steven
Yen, Katharine
Pandya, Shuchi
Clarke, Jennifer
NEURO-ONCOLOGY, 2018, 20 : 234 - 234
[38] Molecular Profiling and Relationship with Clinical Response in Patients with IDH1 Mutation-Positive Hematologic Malignancies Receiving AG-120, a First-in-Class Potent Inhibitor of Mutant IDH1, in Addition to Data from the Completed Dose Escalation Portion of the Phase 1 Study
DiNardo, Courtney
de Botton, Stephane
Pollyea, Daniel A.
Stein, Eytan M.
Fathi, Amir T.
Roboz, Gail J.
Collins, Robert
Swords, Ronan T.
Flinn, Ian W.
Altman, Jessica K.
Tallman, Martin S.
Kantarjian, Hagop M.
Derti, Adnan
Goldwasser, Meredith
Prahl, Malia
Wu, Bin
Yen, Katherine
Agresta, Sam
Stone, Richard M.
BLOOD, 2015, 126 (23)
[39] Preclinical characteristic of HMPL-306, a CNS-penetrable dual inhibitor of mutant IDH1 and IDH2
Yang, Na
Hu, Jia
Li, Tingwen
Yu, Juntao
Shi, Dongxia
Cheng, Min
Zhong, Zeyu
Wang, Jian
Sai, Yang
Qing, Weiguo
Dai, Guangxiu
Ren, Yongxin
Shi, Michael
Su, Weiguo
CANCER RESEARCH, 2023, 83 (07)
[40] Clinical safety and activity in a phase I trial of AG-120, a first in class, selective, potent inhibitor of the IDH1-mutant protein, in patients with IDH1 mutant positive advanced hematologic malignancies
Pollyea, D. A.
de Botton, S.
Fathi, A. T.
Stein, E. M.
Tallman, M. S.
Agresta, S.
Bowden, C.
Fan, B.
Prah, M.
Yang, H.
Yen, K.
Stone, R. M.
EUROPEAN JOURNAL OF CANCER, 2014, 50 : 195 - 195

← 1 2 3 4 5 →